VisionSys AI Inc
VSANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for VSA. That does not mean none is planned.
Get an email about VSA's next catalysts
Track VisionSys AI (VSA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Rebamipide ophthalmic
Dry Eye Syndrome
GB-102
Neovascular Age-Related Macular Degeneration
Preservative-free investigational lubricating eye drops in a Novelia® eyedropper
Visual Acuity
Fluorometholone
Fuchs' Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rebamipide ophthalmic | Phase 3 | Dry Eye Syndrome | - | - |
GB-102 | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Phase 2 | Visual Acuity | - | - |
Fluorometholone | Phase 2 | Fuchs' Dystrophy | - | - |
Frequently asked questions
What is in VisionSys AI Inc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in VisionSys AI Inc's (VSA) pipeline across Phase 3, Phase 2. Its lead program is Rebamipide ophthalmic (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VisionSys AI Inc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VisionSys AI Inc (VSA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VSA biotech catalysts?→
Add VSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VisionSys AI Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
